Össur hf: Q1 2022 Results - Conference Call Tuesday 26 April at 9:00 CEST
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Pressmeddelande

Össur hf: Q1 2022 Results - Conference Call Tuesday 26 April at 9:00 CEST

Announcement no. 23/2022

12 April 2022

Conference call on Tuesday 26 April at 9:00 CEST / 7:00 GMT / 3:00 ET

Össur will publish its financial results for Q1 2022 prior to market opening on Tuesday 26 April. That same day at 9:00 CEST, Össur will host a conference call where Sveinn Solvason, President and CEO, will present and discuss the results of the quarter. The conference call will be conducted in English.

A webcast can be followed on the Össur website: http://www.ossur.com/investors

To participate in the conference call, please call one of the following telephone numbers:

DK: + 45 35 44 55 77

UK: + 44 (0) 333 300 0804

SE: + 46 (0) 8 566 426 51

US: + 1 631 913 1422

IS: + 354 800 7437

The PIN CODE to access the call is 48782473#.

Further information

Edda Lára Lúðvígsdóttir, Investor Relations Director, [email protected], +354 844 4759

Össur press releases by e-mail

If you wish to receive Össur press releases by e-mail, please register at http://www.ossur.com/investors

About Össur

Össur (Nasdaq Copenhagen: OSSR) is a global leader in non-invasive orthopaedics that helps people live a Life Without Limitations. A recognized “Technology Pioneer” with a rich 50-year history, Össur focuses on improving people’s mobility through the delivery of innovative technologies in Prosthetics and Bracing & Supports. Significant investment in research and development have led to over 2,000 patents, award-winning designs, successful clinical outcomes, and consistently strong market positions. Össur is signatory to the UN Global Compact, UN Women’s Empowerment Principles, contributes to the UN Sustainable Development Goals and became carbon neutral in 2021. Össur operates globally and employs around 4,000 employees. www.ossur.com

Nyheter om Embla Medical

Läses av andra just nu

Om aktien Embla Medical

Senaste nytt